Zanoterone

Anti-ZAR1L zygote arrest 1-like, 25ul UN 1687 6.1 PG2

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

Warning Toxicity: Standard Handling (A) Legal Information NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany

The major CYP3A4 metabolite of amiodarone used as an analytical reference standard for monitoring clinical efficacy of amiodarone in plasma samples.

The major CYP3A4 metabolite of amiodarone used as an analytical reference standard for monitoring clinical efficacy of amiodarone in plasma samples.

The major CYP3A4 metabolite of amiodarone used as an analytical reference standard for monitoring clinical efficacy of amiodarone in plasma samples.

The major CYP3A4 metabolite of amiodarone used as an analytical reference standard for monitoring clinical efficacy of amiodarone in plasma samples.

Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC 50 s of 12 and 1 nM against EGFR L858R and EGFR L858R/T790M , respectively.In VitroOsimertinib (AZD-9291) shows similar potency to early

Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC 50 s of 12 and 1 nM against EGFR L858R and EGFR L858R/T790M , respectively.In VitroOsimertinib (AZD-9291) shows similar potency to early

Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC 50 s of 12 and 1 nM against EGFR L858R and EGFR L858R/T790M , respectively.In VitroOsimertinib (AZD-9291) shows similar potency to early

Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC 50 s of 12 and 1 nM against EGFR L858R and EGFR L858R/T790M , respectively.In VitroOsimertinib (AZD-9291) shows similar potency to early